SCHEMBL8500242

SCHEMBL8500242

CC(C)(C)c1cc(O)c(-c2ccccn2)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.50
▸ ALOX15 P16050 5/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ CYP1A2 P05177 2/20 0.50
▸ MAPT P10636 1/20 0.50
▸ ATP2A2 P16615 1/20 0.50
▸ ATP2A3 Q93084 1/20 0.50
▸ KDM1A O60341 4/20 0.44
▸ LMNA P02545 5/20 0.42
▸ CCR1 P32246 2/20 0.42
▸ CCR5 P51681 2/20 0.42
▸ CCR8 P51685 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ METAP1 P53582 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ DOHH Q9BU89 1/20 0.42
▸ P4HTM Q9NXG6 1/20 0.42
▸ TDP1 Q9NUW8 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11124529 0.79 ALDH1A1 (0.46) KDM4EALOX15ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL9258894 0.77 KDM4E (0.50) KDM4EALOX15ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL14821700 0.76 HSP90AA1 (0.49) KDM4ECYP1A2LMNACCR1CCR5
SCHEMBL30178546 0.76 HSP90AA1 (0.49) KDM4ECYP1A2LMNACCR1CCR5
SCHEMBL30022592 0.75 KDM4E (0.48) KDM4EALOX15ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL25428854 0.75 ALDH1A1 (0.52) KDM4EALOX15ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL9158343 0.75 CA2 (0.53) KDM4EALDH1A1SMN1; SMN2CYP1A2LMNA
SCHEMBL14864032 0.75 METAP2 (0.44) KDM4EALOX15ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL16627992 0.74 METAP2 (0.42) KDM4EALOX15ALDH1A1CYP1A2LMNA
SCHEMBL19229871 0.73 KDM4E (0.44) KDM4EALOX15ALDH1A1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36256-E ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-20 — — US disclosed
US-5795889-A INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-08-18 — — US disclosed
EP-0584222-B1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1997-10-08 — — EP disclosed
US-5656643-A QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-08-12 — — US disclosed
US-5646153-A INHIBITING ABNORMAL CELL PROLIFERATION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-08 — — US disclosed
US-5480883-A Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-01-02 — — US disclosed
US-5409930-A Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-04-25 — — US disclosed
EP-0584222-A4 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1994-07-06 — — EP disclosed
EP-0584222-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. RHONE POULENC RORER INT (US) 1994-03-02 — — EP disclosed
WO-1992020642-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 — — WO disclosed
Send feedback